ESC Premium Access

Conclusion and key takeaways

Congress Presentation

About the speakers

Professor J Wouter Jukema

Leiden University Medical Center, Leiden (Netherlands (The))
20 presentations
0 follower

Professor Francois Schiele

Regional University Hospital Jean Minjoz, Besancon (France)
15 presentations
0 follower

Doctor Christie Ballantyne

Baylor College of Medicine, Houston (United States of America)
22 presentations
2 followers

5 more presentations in this session

Introduction

Speaker: Professor J. Jukema (Leiden, NL)

Thumbnail

The need for urgency in treating hyperlipidemia in post-ACS patients

Speaker: Professor F. Schiele (Besancon, FR)

Thumbnail

Enriching the PCSK9i evidence - The most recent analyses from ODYSSEY OUTCOMES

Speaker: Professor J. Jukema (Leiden, NL)

Thumbnail

Evaluating the benefit/risk and safety profile of PCSK9 inhibitors - Clinical and economic implications

Speaker: Doctor C. Ballantyne (Houston, US)

Thumbnail

Panel discussion

Speaker: Professor J. Jukema (Leiden, NL) Professor F. Schiele (Besancon, FR) Doctor C. Ballantyne (Houston, US)

Thumbnail

Access the full session

Evolving scientific evidence with PCSK9 inhibitors based on ODYSSEY outcomes

Speakers: Professor J. Jukema, Professor F. Schiele, Doctor C. Ballantyne, Professor J. Jukema, Professor F. Schiele...
Thumbnail

About the event

Image

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb